Clinical Trials Logo
  1. Home
  2. CLL
  3. NCT01397916
  4. Details
NCT01397916 Clinical Trial

Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)

CLL Clinical Trial

— KLL3  

Official title:
The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01397916
Other study ID # CLL-IDO
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 2010
Est. completion date December 2010

Study information
Verified date February 2022
Source Tampere University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.

Description:

The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.

Recruitment information / eligibility
Status Completed
Enrollment 73
Est. completion date December 2010
Est. primary completion date December 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 85 Years
Eligibility Inclusion Criteria: - Patients with CLL and lymphocyte count > 10 x 109/l Exclusion Criteria: - Acute infection

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Finland Tampere university Hospital Tampere

Sponsors (1)
Lead Sponsor Collaborator
Tampere University Hospital

Country where clinical trial is conducted

Finland, 

Outcome
Type Measure Description Time frame Safety issue
Primary IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells. Indoleamine 2,3 -dioxygenase (IDO) activity in patients with CLL was measured by the serum kynurenine/tryptophan (kyn/trp) ratio and - the expression of INDO (encoding IDO enzyme) and INDOL1 (encoding IDO2 enzyme) genes in peripheral blood mononuclear cells via TaqMan real-time PCR. 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02229422 - A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) Phase 1/Phase 2
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01862445 - Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
Completed NCT00535873 - Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older Phase 2
Withdrawn NCT03639324 - Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Phase 1
Recruiting NCT05517265 - Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
Recruiting NCT03868722 - Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment Phase 2/Phase 3
Recruiting NCT04640909 - Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients N/A
Recruiting NCT05610228 - Study of the Metabolism in the Lymphatic Niche of CLL
Completed NCT01168921 - Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Phase 2
Withdrawn NCT05209308 - Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL Phase 2
Completed NCT00792077 - A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue Phase 2
Recruiting NCT06073821 - Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Phase 3
Recruiting NCT05246345 - Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Terminated NCT01532635 - A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Phase 2
Completed NCT01703364 - Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL Phase 1/Phase 2
Terminated NCT03572634 - Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL Phase 1/Phase 2
Completed NCT03231579 - Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study
Completed NCT00636909 - Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Phase 2
Active, not recruiting NCT03524235 - Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL Phase 1